GSK's AIDS vaccine gives protection in monkeys
GlaxoSmithKline has reported the results of a study which shows that itsrecombinant candidate HIV vaccine, which combines several HIV antigens plus a proprietary adjuvant, AS02A, confers long-lasting protection from simian-human immunodeficiency virus in rhesus monkeys. The protection persisted for more than 18 months after immunization and monitoring of the monkeys is still ongoing.
Gerald Voss, a senior scientist at GSK, said that the "unique candidate vaccine appears to be highly effective against the development of the disease and may reduce the rate of transmission." The company will develop its vaccine candidate against at least two strains of HIV, and expects it to enter Phase I clinical trials with the National Institute of Allergy and Infectious Diseases HIV Vaccine Trial Network in the USA by the end of this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze